Bristol Taxol Kaposi's sarcoma labeling cites increased toxicity with higher recommended dose.
Executive Summary
TAXOL KAPOSI's SARCOMA LABELING NOTES GREATER TOXICITY WITH HIGHER DOSE used in the Phase II studies of the Bristol-Myers Squibb paclitaxel product. In clinical trials for AIDS-related Kaposi's sarcoma patients, "135 mg/m2 every three weeks was more toxic" than 100 mg/m2 every two weeks and "all the patients with low performance status were treated with the latter schedule," labeling notes. The indication was approved Aug. 4 ("The Pink Sheet" Aug. 11, T&G-1).